ClinicalTrials.govpublic full text
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
plaque psoriasis, deucravacitinib, cardiovascular risk, pragmatyk, interventional, phase3
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 812786
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.